Rhythm Pharma: MHRA Expands Marketing Authorization For IMCIVREE - Quick Facts

December 03, 2024 — 06:24 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - Rhythm Pharmaceuticals (RYTM) announced that the United Kingdoms Medicines & Healthcare products Regulatory Agency or MHRA has expanded the marketing authorization for IMCIVREE or setmelanotide to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome or genetically confirmed loss-of-function biallelic pro-opiomelanocortin, including proprotein convertase subtilisin/kexin type 1, deficiency or biallelic leptin receptor deficiencyin adult and pediatric patients as young as 2 years old and older.

IMCIVREE initially received marketing authorization from the MHRA as an option for treating obesity and control of hunger in patients aged 6 years and older in these indications in 2022. A supplemental New Drug Application for IMCIVREE for patients as young as 2 years of age is currently under priority review with the FDA, with an assigned PDUFA goal date of December 26, 2024.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Rhythm Pharma: MHRA Expands Marketing Authorization For IMCIVREE - Quick Facts

Tags

Latest Articles